読み込み中
NASDAQHealthcareMedical - Instruments & Supplies
最新データ
$26.98
+$1.21 · +4.70%
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
前日終値
$26.98
+$1.21 · +4.70%
日中の時刻はETです。市場データは遅延する場合があります。
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
日中レンジ
現在 $26.98
52週レンジ
現在 $26.98
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
62
割安
センチメント
41
まちまち
リスク
45
やや高いリスク
モメンタム
64
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
日中レンジ
現在 $26.98
52週レンジ
現在 $26.98
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 |
|---|---|---|---|---|
| 売上高 | 9512.7万 USD | 5981.5万 USD | 2781.4万 USD | 763万 USD |
| 売上原価 | 4626.3万 USD | 3560.5万 USD | 2745.2万 USD | 1828.1万 USD |
| 粗利益 | 4886.4万 USD | 2421万 USD | 36.2万 USD | −1065.1万 USD |
| 研究開発 | 1948.3万 USD | 1565.2万 USD | 1549万 USD | 1575.6万 USD |
| 販売・一般管理 | 1.64億 USD | 1.15億 USD | 6993.5万 USD | 5401.4万 USD |
| 営業費用 | 1.84億 USD | 1.31億 USD | 8542.5万 USD | 6977万 USD |
| 受取利息 | 835.1万 USD | 319.9万 USD | — | — |
| 支払利息 | 754.7万 USD | 773.4万 USD | 623万 USD | 562.9万 USD |
| 減価償却費と償却費 | 870.9万 USD | 796.8万 USD | 1156万 USD | 485.5万 USD |
| 営業利益 | −1.35億 USD | −1.06億 USD | −8506.3万 USD | −8042.1万 USD |
| 純利益 | −1.32億 USD | −1.14億 USD | −9412万 USD | −8423.8万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$30.67
上昇余地（13.68%）評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2387.51万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1825.15万0.02%787.4億 USD0.19%$278.94+0.49%
First Trust Small Cap Growth AlphaDEX FundFYC652.54万0.48%13.49億 USD0.70%$115.36+1.35%
iShares Russell 2000 Growth ETFIWO630.38万0.05%139.17億 USD0.24%$356.78+0.94%
Vanguard Extended Market ETFVXF580.92万0.01%954億 USD0.05%$235+0.80%
Schwab U.S. Small-Cap ETFSCHA454.03万0.02%218.24億 USD0.03%$32.79+0.40%
iShares U.S. Medical Devices ETFIHI418.4万0.12%35.74億 USD0.37%$51.74+1.25%
Vanguard Russell 2000 ETFVTWO396.62万0.02%180億 USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares U.S. Medical Devices ETFIHIVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
